Arvinas Holding Company LLC (ARVN)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
John G. Houston
Employees:
280
395 WINCHESTER COMPANY, LLC, 5 SCIENCE PARK, NEW HAVEN, CT 06511
203-535-1456

Arvinas, Inc. engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC)

Data derived from most recent annual or quarterly report
Market Cap 1.594 Billion Shares Outstanding53.228 Million Avg 30-day Volume 444.522 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-3.82
Price to Revenue21.0951 Debt to Equity0.0016 EBITDA-230.9 Million
Price to Book Value3.8083 Operating Margin-222.72729999999999 Enterprise Value1.092 Billion
Current Ratio5.334 EPS Growth-0.245 Quick Ratio5.223
1 Yr BETA 1.6383 52-week High/Low 75.39 / 26.57 Profit Margin-225.0446
Operating Cash Flow Growth-142.0394 Altman Z-Score1.4858 Free Cash Flow to Firm -264.306 Million
Earnings Report2023-05-04
View SEC Filings from ARVN instead.

View recent insider trading info

Funds Holding ARVN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ARVN

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2023-03-10:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2023-02-23:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-09:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-08:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
  • 8-K: filed on 2022-11-22:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-22:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-22:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2022-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-19:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • Proposed Sales (Form 144)

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    8.7 Thousand total shares from 3 transactions

    Exercise Derivative Conversion (M)

    25 Thousand total shares from 3 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    CASSIDY SEAN A CHIEF FINANCIAL OFFICER

    • Officer
    183,618 2023-03-01 2

    TAYLOR IAN CHIEF SCIENTIFIC OFFICER

    • Officer
    101,721 2023-03-01 3

    HOUSTON JOHN G PRESIDENT AND CEO

    • Officer
    • Director
    917,427 2023-03-01 2

    PECK RONALD CHIEF MEDICAL OFFICER

    • Officer
    27,279 2023-02-22 3

    CUNNINGHAM EVERETT

    • Director
    0 2022-12-15 2

    LOOMIS DAVID K CHIEF ACCOUNTING OFFICER

    • Officer
    2,750 2022-12-15 1

    YOUNG JOHN D

    • Director
    24,572 2022-08-18 2

    DIXON WENDY L

    • Director
    10,192 2022-06-16 1

    SHANNON TIMOTHY M

    • Director
    10,192 2022-06-16 1

    NORWALK LESLIE V

    • Director
    10,192 2022-06-16 1

    RATCLIFFE LIAM

    • Director
    10,192 2022-06-16 1

    BAIN LINDA

    • Director
    10,192 2022-06-16 1

    SMALDONE ALSUP LAURIE

    • Director
    10,192 2022-06-16 1

    MORRISON BRIGGS

    • Director
    10,192 2022-06-16 2

    MARGUS BRADLEY ALBERT

    • Director
    10,192 2022-06-16 1

    KENNEDY EDWARD MOORE JR.

    • Director
    10,192 2022-06-16 1

    CANAAN IX L.P.

    CANAAN PARTNERS IX LLC

    • 10% Owner
    No longer subject to file 2020-10-14 0

    LOVEN JAKOB

    • Director
    0 2020-06-03 0

    PARMAR KUSH

    • Director
    1,775 2019-09-24 0

    5AM VENTURES III, L.P.

    5AM PARTNERS III, LLC

    5AM CO-INVESTORS III, L.P.

    DIEKMAN JOHN D

    ROCKLAGE SCOTT M

    SCHWAB ANDREW J.

    • 10% Owner
    3,316,059 2019-09-16 0

    CREW ANDREW SEE REMARKS

    • Officer
    0 2019-03-01 0

    FLYNN JAMES E

    DEERFIELD MGMT L.P.

    DEERFIELD MGMT III, L.P.

    DEERFIELD MGMT IV, L.P.

    DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    DEERFIELD PRIVATE DESIGN FUND III, L.P.

    DEERFIELD PRIVATE DESIGN FUND IV, L.P.

    • 10% Owner
    • POSSIBLE MEMBER OF A 10% GROUPPOSSIBLE MEMBER OF A 10% GROUPPOSSIBLE MEMBER OF A 10% GROUPPOSSIBLE MEMBER OF A 10% GROUPPOSSIBLE MEMBER OF A 10% GROUPPOSSIBLE MEMBER OF A 10% GROUPPOSSIBLE MEMBER OF A 10% GROUPPOSSIBLE MEMBER OF A 10% GROUP
    No longer subject to file 2018-10-01 0

    RA CAPITAL MANAGEMENT, LLC

    RA CAPITAL HEALTHCARE FUND LP

    KOLCHINSKY PETER

    • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    No longer subject to file 2018-10-01 0

    CONNECTICUT INNOVATIONS INC

    • 10% Owner
    0 2018-09-26 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VI LLC

    • 10% Owner
    0 2018-09-26 0

    ELM STREET VENTURES L P

    ELM STREET VENTURE ASSOCIATES, LLC

    BETTIGOLE ROBERT A.

    • 10% Owner
    0 2018-09-26 0

    NEW LEAF VENTURES III, L.P.

    NEW LEAF VENTURE ASSOCIATES III, L.P.

    NEW LEAF VENTURE MANAGEMENT III, L.L.C.

    • 10% Owner
    0 2018-09-26 0

    CRAIG M. CREWS FAMILY 2013 TRUST

    • 10% Owner
    560,000 2018-09-26 0

    CREWS FAMILY 2018 TRUST

    • 10% Owner
    538,461 2018-09-26 0

    CREWS CRAIG MARTIN

    • 10% Owner
    2,106,692 2018-09-26 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    CASSIDY SEAN A - Officer CHIEF FINANCIAL OFFICER

    2023-03-03 21:49:25 -0500 2023-03-01 S 1,745 $29.53 d 183,618 direct -2.1029 -7.5057 0.0 1 -12.5526 5

    TAYLOR IAN - Officer CHIEF SCIENTIFIC OFFICER

    2023-03-03 21:51:13 -0500 2023-03-01 M 2,685 d 0 direct

    TAYLOR IAN - Officer CHIEF SCIENTIFIC OFFICER

    2023-03-03 21:51:13 -0500 2023-03-01 M 2,685 a 102,772 direct -2.1029 -7.5057 0.0 1 -12.5526 5

    TAYLOR IAN - Officer CHIEF SCIENTIFIC OFFICER

    2023-03-03 21:51:13 -0500 2023-03-01 S 1,051 $29.53 d 101,721 direct -2.1029 -7.5057 0.0 1 -12.5526 5

    HOUSTON JOHN G - Director - Officer PRESIDENT AND CEO

    2023-03-03 21:50:14 -0500 2023-03-01 M 17,510 d 0 direct

    HOUSTON JOHN G - Director - Officer PRESIDENT AND CEO

    2023-03-03 21:50:14 -0500 2023-03-01 M 17,510 a 923,305 direct -2.1029 -7.5057 0.0 1 -12.5526 5

    HOUSTON JOHN G - Director - Officer PRESIDENT AND CEO

    2023-03-03 21:50:14 -0500 2023-03-01 S 5,878 $29.53 d 917,427 direct -2.1029 -7.5057 0.0 1 -12.5526 5

    CASSIDY SEAN A - Officer CHIEF FINANCIAL OFFICER

    2023-03-03 21:49:25 -0500 2023-03-01 M 4,791 d 0 direct

    CASSIDY SEAN A - Officer CHIEF FINANCIAL OFFICER

    2023-03-03 21:49:25 -0500 2023-03-01 M 4,791 a 185,363 direct -2.1029 -7.5057 0.0 1 -12.5526 5

    TAYLOR IAN - Officer CHIEF SCIENTIFIC OFFICER

    2023-02-24 16:56:46 -0500 2023-02-22 A 19,125 a 100,087 direct 0.2617 1.1122 2.6824 5 -0.5561 4

    CASSIDY SEAN A - Officer CHIEF FINANCIAL OFFICER

    2023-02-24 16:59:35 -0500 2023-02-22 A 57,450 a 57,450 direct

    CASSIDY SEAN A - Officer CHIEF FINANCIAL OFFICER

    2023-02-24 16:59:35 -0500 2023-02-22 A 19,125 a 180,572 direct 0.2617 1.1122 2.6824 5 -0.5561 4

    HOUSTON JOHN G - Director - Officer PRESIDENT AND CEO

    2023-02-24 16:57:43 -0500 2023-02-22 A 186,250 a 186,250 direct

    HOUSTON JOHN G - Director - Officer PRESIDENT AND CEO

    2023-02-24 16:57:43 -0500 2023-02-22 A 61,975 a 905,795 direct 0.2617 1.1122 2.6824 5 -0.5561 4

    PECK RONALD - Officer CHIEF MEDICAL OFFICER

    2023-02-24 16:58:36 -0500 2023-02-22 A 57,450 a 57,450 direct

    PECK RONALD - Officer CHIEF MEDICAL OFFICER

    2023-02-24 16:58:36 -0500 2023-02-22 A 19,125 a 27,279 direct 0.2617 1.1122 2.6824 5 -0.5561 4

    TAYLOR IAN - Officer CHIEF SCIENTIFIC OFFICER

    2023-02-24 16:56:46 -0500 2023-02-22 A 57,450 a 57,450 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ARVINAS INC ARVN 2023-03-20 13:45:03 UTC 4.16 0.41 700000
    ARVINAS INC ARVN 2023-03-20 13:15:04 UTC 4.16 0.41 700000
    ARVINAS INC ARVN 2023-03-20 12:45:03 UTC 4.16 0.41 700000
    ARVINAS INC ARVN 2023-03-17 22:15:03 UTC 4.16 0.41 700000
    ARVINAS INC ARVN 2023-03-17 21:45:03 UTC 4.16 0.41 700000
    ARVINAS INC ARVN 2023-03-17 21:15:03 UTC 4.16 0.41 700000
    ARVINAS INC ARVN 2023-03-17 20:45:03 UTC 4.16 0.41 700000
    ARVINAS INC ARVN 2023-03-17 20:15:06 UTC 4.16 0.41 700000
    ARVINAS INC ARVN 2023-03-17 19:45:03 UTC 4.16 0.41 700000
    ARVINAS INC ARVN 2023-03-17 19:15:03 UTC 4.16 0.41 700000
    ARVINAS INC ARVN 2023-03-17 18:45:03 UTC 4.16 0.41 700000
    ARVINAS INC ARVN 2023-03-17 18:15:03 UTC 4.16 0.41 700000
    ARVINAS INC ARVN 2023-03-17 17:45:04 UTC 4.16 0.41 700000
    ARVINAS INC ARVN 2023-03-17 17:15:05 UTC 4.16 0.41 700000
    ARVINAS INC ARVN 2023-03-17 16:45:03 UTC 4.1402 0.4298 700000
    ARVINAS INC ARVN 2023-03-17 16:15:04 UTC 4.1402 0.4298 700000
    ARVINAS INC ARVN 2023-03-17 15:45:04 UTC 4.1402 0.4298 700000
    ARVINAS INC ARVN 2023-03-17 15:15:03 UTC 4.1402 0.4298 700000
    ARVINAS INC ARVN 2023-03-17 14:45:03 UTC 4.1402 0.4298 700000
    ARVINAS INC ARVN 2023-03-17 14:15:04 UTC 4.1402 0.4298 700000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    VANGUARD MONTGOMERY FUNDS- VANGUARD MARKET NEUTRAL FUND ARVN -93914.0 shares, $-3212797.94 2022-12-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments